2015 Press Releases

Home»2015 Press Releases
20 07, 2015

The Lancet Publishes Results of Phase 2 Study of Lonafarnib in HDV Infected Patients

2017-02-07T18:56:59+00:00

The Lancet Publishes Results of Phase 2 Study of Lonafarnib in HDV Infected Patients Palo Alto, Calif., July 20, 2015 / PRNewswire/ — Eiger BioPharmaceuticals Incorporated announced today the publication of results of the first Phase 2a study of lonafarnib in patients with chronic hepatitis delta virus (HDV) infection. The study was conducted [...]

The Lancet Publishes Results of Phase 2 Study of Lonafarnib in HDV Infected Patients2017-02-07T18:56:59+00:00
28 04, 2015

Eiger Bio Announces Interim Results of Lonafarnib in Combination with Ritonavir or Pegylated Interferon in Patients Infected with Hepatitis Delta Virus (HDV)

2017-02-07T18:58:15+00:00

Eiger Bio Announces Interim Results of Lonafarnib in Combination with Ritonavir or Pegylated Interferon in Patients Infected with Hepatitis Delta Virus (HDV) PALO ALTO, Calif., April 27, 2015 /PRNewswire/ -- Eiger BioPharmaceuticals, Incorporated today announced the presentation of interim results of Phase 2 data of lonafarnib in patients with chronic hepatitis delta viral [...]

Eiger Bio Announces Interim Results of Lonafarnib in Combination with Ritonavir or Pegylated Interferon in Patients Infected with Hepatitis Delta Virus (HDV)2017-02-07T18:58:15+00:00
20 04, 2015

FDA Grants Fast Track Designation to Eiger Bio’s Lonafarnib for Hepatitis Delta Virus (HDV) Infection

2017-02-07T18:59:25+00:00

FDA Grants Fast Track Designation to Eiger Bio's Lonafarnib for Hepatitis Delta Virus (HDV) Infection PALO ALTO, Calif., April 20, 2015 /PRNewswire/ -- Eiger BioPharmaceuticals, Incorporated today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its lead product candidate, lonafarnib, in combination with ritonavir for treatment [...]

FDA Grants Fast Track Designation to Eiger Bio’s Lonafarnib for Hepatitis Delta Virus (HDV) Infection2017-02-07T18:59:25+00:00
14 04, 2015

Eiger BioPharmaceuticals Announces Senior Staff Appointments in Clinical Development and Regulatory Affairs: Dr. Joanne Quan, M.D., as Chief Medical Officer & Dr. Shelly Xiong, Ph.D., as Vice President of Regulatory Affairs

2017-02-07T19:00:48+00:00

Eiger BioPharmaceuticals Announces Senior Staff Appointments in Clinical Development and Regulatory Affairs: Dr. Joanne Quan, M.D., as Chief Medical Officer & Dr. Shelly Xiong, Ph.D., as Vice President of Regulatory Affairs PALO ALTO, Calif., April 14, 2015 /PRNewswire/ -- Eiger BioPharmaceuticals, Incorporated, a biopharmaceutical company focused on the development and commercialization of therapies [...]

Eiger BioPharmaceuticals Announces Senior Staff Appointments in Clinical Development and Regulatory Affairs: Dr. Joanne Quan, M.D., as Chief Medical Officer & Dr. Shelly Xiong, Ph.D., as Vice President of Regulatory Affairs2017-02-07T19:00:48+00:00
13 04, 2015

Eiger Bio Announces Abstracts and Presentations of Lonafarnib Data in HDV at the EASL Conference – 2015

2017-02-07T19:02:34+00:00

Eiger BioPharmaceuticals Announces Abstracts and Presentations of Lonafarnib Data in Hepatitis Delta (HDV) at the European Association for the Study of the Liver Conference – April 22 to 26, 2015 PALO ALTO, Calif., April 13, 2015 /PRNewswire/ -- Eiger BioPharmaceuticals Incorporated, today announced that abstracts from its Hepatitis Delta Virus (HDV) development program [...]

Eiger Bio Announces Abstracts and Presentations of Lonafarnib Data in HDV at the EASL Conference – 20152017-02-07T19:02:34+00:00
23 02, 2015

Eiger Announces Presentation of Positive Data in Patients Treated with Lonafarnib

2017-02-07T19:05:57+00:00

Eiger BioPharmaceuticals Announces Presentation of Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib - NIH Principal Investigator to Present Abstract and Poster at Conference on Retroviruses and Opportunistic Infections (CROI) Palo Alto, Calif., February 23, 2015 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. announced today that positive results of a [...]

Eiger Announces Presentation of Positive Data in Patients Treated with Lonafarnib2017-02-07T19:05:57+00:00